Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Essential Tremor Subjects must be between the ages of 18 and 80 inclusive. 2. Each subject must have current manifestations of ET symptoms based on the Tremor Investigational Group (TRIG) for definite or probable ET Moderate or severe tremor in head or arms for at least 3 years duration No present causes of enhanced physiologic tremor No recent exposure to tremorogenic drugs or drug withdrawal states No direct or indirect trauma to the nervous system within 3 months preceding the onset of tremor No historic or clinical evidence of psychogenic tremor origin. 3. Subjects with a history of seizures are eligible. 4. Subjects must be in generally good health as evidenced by previous medical history and clinical examination. 5. Patients will be allowed to take Beta-blockers but will not be allowed to take any other medication for tremor (primidone, topiramate, benzodiazepines, etc.) An evening dose of a benzodiazepine to improve sleep is acceptable. They must have been on a stable dose of any existing beta-blocker for 4 weeks prior to entry into the study and will not be allowed to change the dose of that medication throughout the controlled portion of the study. Any medication discontinued during screening in order to comply with these must be stopped for 5 half-lives prior to study initiation. 6. Subjects must be accessible by telephone. 7. If the subject is a female of childbearing age, she must have had a hysterectomy, tubal ligation, otherwise be incapable of pregnancy, or have practiced one of the following methods of contraception for at least one month prior to study entry (or a negative urine pregnancy test within one week of study entry) Hormonal contraceptives Spermicide and barrier Intrauterine device Partner sterility 8. Prior to participation in this study, each subject must sign an informed consent  Patients do not meet TRIG for probable ET. 2. Subjects who are not able to abstain from alcohol for 24 hours prior to each evaluation. 3. Patients who can not maintain an identical dose of any medicine that may affect tremor during their entire study involvement. 4. Subjects who have exhibited any psychotic symptomatology. 5. Subjects who have known renal deficiencies. 6. Subjects who have been intolerant of pregabalin in the past 7. Prior surgical treatment for tremor. 8. Patients currently taking more than a single drug for ET. 9. Patients taking anti-seizure medications. 10. Breast feeding or pregnant females